Starting in 1997, we began treating patients with a single brain metastasis requiring resection with GKS directed to the resection bed as an alternative to postoperative WBRT. This strategy was intended primarily to maximize long-term local tumor control and concomitantly to avoid the proposed, albeit not proven, long-term complications of WBRT. Selection for GKS as an alternative to WBRT was not systematic but reflected the physician's and patient's preference. Surgery was indicated for all patients who harbored relatively large (> 2.5 cm) symptomatic lesions to palliate their neurological symptoms and to confirm the diagnosis of metastatic disease histologically. Patients with smaller asymptomatic lesions and an established cancer diagnosis were treated with GKS or WBRT without resection during this period, but those patients were not included in this study.
Methods

Patient Selection
We retrospectively identified all patients at our institution who underwent resection for a single metastasis followed by GKS between April 1997 (when our Gamma Knife Center opened) and September 2009. Patients with multiple cerebral metastases, those who underwent subtotal resection, and those who received WBRT were excluded from the study.
Gamma Knife Technique
Patients undergoing GKS were treated with the Leksell model B (1997) (1998) (1999) (2000) (2001) (2002) , model C (2002-2008), or Perfexion (2008-2009) Gamma Knife system (Elekta AB) at our institution's Gamma Knife Center. All patients were placed in a state of anesthesia for placement of the stereotactic frame. After the frame had been placed, a stereotactic imaging modality, usually MR imaging but occasionally CT, was used for surgical planning. Treatment planning was performed using GammaPlan software (Elekta AB). For all patients, the outlined target encompassed a 1-3-mm margin of brain tissue around the entire tumor resection bed. Software drawing tools were used to create outlines on each 1-mm image slice. Target volumes were calculated using GammaPlan software. Appropriate dose limitations for critical radiosensitive structures, such as the optic apparatus, were followed when necessary. The treatment dose was typically directed at the 50% isodose line (range 50%-76% isodose line), at the margin of the resection bed (Fig. 1) . The surgical access track for deep lesions was not specifically targeted. The median margin dose was 15 Gy (range 14-30 Gy) and depended on the volume of the cavity and the location of lesion. A 30-Gy dose was used in a single isolated case for a large lesion; in the majority of cases the 15-Gy dose was used.
Follow-Up and Survival
Follow-up and survival data were obtained in all patients. When available, follow-up neuroimages were reviewed and analyzed for recurrence of treated metastasis and development of distant metastases. Survival curves from diagnosis of the primary cancer or the initiation of treatment for the metastasis to time of death or last follow-up were calculated using the method of Kaplan and Meier 10 and compared using the log-rank statistic. We also generated Kaplan-Meier curves based on pretreatment KPS scores as well as curves for tumor recurrence when the data were available. Patient sex and age at resection of metastasis, presence of extracranial systemic disease, and intracranial treatment failure (local tumor recurrence or distant intracranial metastases) were also analyzed. Where appropriate, we used a Student t-test to identify statistically significant differences between the data sets. Tumors were characterized as more radiosensitive, meaning they displayed a good response to radia- * NR = not reported.
Fig. 1.
Radiosurgical treatment plan for a single occipital lobe brain metastasis resection bed. The 50% and 30% isodense lines shown in the axial plane document conformability to the slope of the resection cavity and delivery of 16 Gy to the margin of resection.
tion treatment (breast, ovarian, and colon cancer), or less ra dio sensitive (NSCLC, melanoma, and esophageal and renal cell cancer). Kaplan-Meier curves for survival and tumor recurrence were generated based on this characterization of the primary tumors.
Results
Patient Demographics
During the study period, 68 patients underwent resection of a single metastasis and radiation treatment using GKS (Table 2) . Thirty-one patients (45.6%) were men and 37 patients (54.4%) were women. Their mean age at GKS was 60 years (range 28-89 years) (Fig. 2) . In most cases the tumors occurred in the frontal lobe followed by the parietal and occipital lobes. In 7 cases tumors involved the parafalcine, periventricular, and interventricular regions. The most frequent types of tumors treated were NSCLC, breast cancer, and melanoma. There were 6 cases of other tumors that included head and neck cancer, sarcoma, cervical cancer, endometrial cancer, and fibrohistiocytoma. The mean duration between resection and GKS was 15.5 days. The mean KPS score at the initial treatment was 90 (range 40-100). In 45 patients (66.2%) there was systemic control of the primary cancer at the time of diagnosis of metastasis. Patients with a pretreatment KPS score of 90 or greater had a median survival of 23.2 months, whereas those with a KPS less than 90 had a median survival of 10 months (p < 0.008) (Fig. 3) .
Radiosurgical Parameters
The median radiation dose to the cavity margin in patients undergoing GKS was 15 Gy (range 14-30 Gy) directed to the 50% isodose line (range 50%-76% isodose line). All patients were treated in a single dose session. The mean volume of the treated cavity was 10.35 cm 3 (range 0.9-45.4 cm 3 ; Table 2 and Fig. 4 ).
Follow-Up and Survival
Median survival, defined as the time from initiation of treatment to the last follow-up was reached at 13.2 months (Fig. 5) . Total survival, defined as the time from the primary cancer to the last follow-up, was reached at 30.2 months (Fig. 6 ). The status of the primary cancer at the time of initiation of treatment did not seem to influence the length of survival (Fig. 7) . Patients with systemic disease lived a median of 12.5 months compared with 19.4 months for those in whom systemic disease could not be detected on available images. Although patients with imaging evidence of disease control tended to survive longer, the data were not significant (p < 0.26). Twenty-seven patients (39.7%) developed tumor recurrence. Median recurrence in the group of patients with a tumor recurrence was 10.6 months (Fig. 8) . The location of the recurrence was confirmed in only 24 patients. The rate of local recurrence or treatment failure at the resection cavity was 20.6%.
Discussion
Surgery followed by WBRT has classically been the standard of care for a single brain metastasis located in a surgically accessible location. [18] [19] [20] 32 Gamma Knife surgery has been established as an effective treatment for many types of brain metastases. 1, 11, 12, 15, 26, 31, 33, 34 Although GKS has been advocated as an alternative to surgery, its role or that of WBRT for the treatment of single metastases remains controversial. 3, 9, 14, 16, 17, 21, 23, 24, 28 In their retrospective analysis, Sanghavi et al. 22 reported that radiosurgery improved survival in patients receiving WBRT for metastases. Sneed et al. 29 demonstrated that radiosurgery alone compared favorably with radiosurgery plus WBRT after surgery for metastases, suggesting that WBRT may not be needed in all cases. Auchter et al. 2 suggested that GKS could be used in lieu of resection for solitary metastasis and that WBRT could be added as an adjunctive treatment. Muacevic et al. 16 compared surgery plus WBRT to GKS and found that local tumor control rates were equal in the 2 groups. The incidence of distant metastases was highest in patients who were treated with GKS only. However, tumor control was achieved with retreatment with GKS, and those authors found no statistically significant difference in survival between the 2 groups. These data have since been reproduced, and some investigators have suggested that WBRT be reserved for patients who experience relapse after radiosurgery treat- ment. 9, 25 There are certain advantages and disadvantages to using GKS instead of WBRT after resection. In general, WBRT delivers a dose of radiation to the entire brain, and some have argued that this is associated with a higher potential for side effects and radiation-induced damage to the uninvolved brain. 4 Based on available follow-up, we can state that GKS achieved good local control (80%) in our hands. It is noteworthy that the local failure rate at the resection bed after whole-brain irradiation is similar between WBRT and radiosurgery. 19 Our experience suggests that in select patients GKS provides a similar survival outcome to published results for WBRT. 19 Patients treated using our protocol with a pretreatment KPS score of 90 or greater had longer survival times than those with a KPS score less than 90 at the initiation of treatment. The "radiosensitivity" of the tumor did not seem to affect survival (data not shown). There were 27 incidences of tumor recurrences (39.7%) in our series. The rate of local recurrence or treatment failure at the resection cavity was 20.6%, indicating that surgery and GKS provide good local control. Although the use of GKS may result in a higher rate of treatment failure relative to WBRT, GKS minimizes the radiation dose to other uninvolved regions of the brain that may affect patients' quality of life. 4 We did not collect information on complications of GKS in every patient, and therefore we cannot draw conclusions on the safety of GKS versus WBRT. The only randomized clinical trial 4 on the deleterious effect of WBRT is disputed because of the poor survival of patients in that series who underwent WBRT. Whether WBRT has a dramatic effect on quality of life in patients remains to be tested appropriately with a better designed randomized control trial.
Cost-Effectiveness of GKS
The cost of GKS, especially in patients who may need to undergo repeat treatment of new metastases, is considerably higher than that of WBRT-nearly 3 times higher, and more at our institution. The cost of repeat treatment, however, is certainly higher than those calculated based only on physician and hospital costs, as there are immeasurable effects on the patient's quality of life, a topic worthy of an independent study. We are not suggesting that GKS be used in all patients harboring a single metastasis. Gamma Knife surgery appears most appropriate for patients with a high chance of long-term survival to avoid the proposed, albeit not proven, delayed cognitive side effects of WBRT. Gamma Knife surgery may not be cost-effective as adjunctive treatment after resection in patients with poorly controlled, widespread extracranial systemic disease or patients with other factors associated with a poor prognosis. However, GKS performed shortly after surgery does allow patients who require chemotherapy to begin treatment without delay, which is not possible with WBRT due to concerns about the added morbidity associated with concurrent chemotherapy and WBRT. One can also argue that if cost was not an issue, a single-day palliative treatment with minimal side effects would be preferable to 10-20 daily WBRT treatments, which cause alopecia, lethargy, and skin sensitivity among other maladies.
These preliminary results indicate that GKS is a reasonable alternative to WBRT after surgery for a single metastasis. The convenience of a single-session outpatient treatment and minimization of short-term and long-term side effects make this approach attractive. A dura-based metastasis with a high likelihood of leptomeningeal spread may be a contraindiction for this treatment approach. Cost issues may limit the use of this treatment to patients with a longer than average prognosis for survival based on systemic disease, burden, and performance status after resection.
Conclusions
Surgery followed by GKS in patients with a single metastasis offers survival times and local tumor control rates that are comparable to surgery followed by WBRT. Should distant metastases develop, retreatment with GKS is an option. Uncontrolled extracranial systemic disease or dura-based tumors may be contraindications for GKS directed at the resection bed of a brain metastasis, although our results indicate that a patient's pretreatment KPS score is a better indicator of survival than systemic control of the disease. This report represents an early analysis of our results with the use of GKS as an adjunct to surgery in lieu of WBRT. Further analysis, including evaluation of rates of radiation necrosis, an evaluation of patient outcome based on the radiosurgical margin and dose gradient, and improved follow-up are needed to better understand the strengths and shortcomings of this technique. Ultimately, a randomized control trial in which WBRT is compared with GKS after resection of a single cerebral metastasis is the ideal venue for the evaluation of these radiation treatment modalities.
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